As part of the company’s strategic pivot to autoimmunity, Fred Schwarzer, CEO, president and director, and Bruce Keyt, chief scientific officer, or CSO, will step down from their current roles at the company. Schwarzer and Keyt are expected to remain as consultants. Chris Takimoto, chief medical officer, is stepping down from his current role to pursue an opportunity outside the company.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IGMS:
- IGM Biosciences to reduce spending on aplitabart, reduce workforce
- IGM Biosciences appoints Mary Beth Harler as CEO
- Biotech Alert: Searches spiking for these stocks today
- IGM Biosciences price target lowered to $11 from $12 at H.C. Wainwright
- IGM Biosciences price target lowered to $24 from $25 at Truist